UNASSIGNED: We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and @entity2903 treatment in inoperable @entity463 @entity1 . A phase II study opened; @entity1 over 18 years of age who were able to give informed consent and had histologically proven, newly diagnosed inoperable diagnosed and @entity463 were eligible. Three doses of 0.75 Gy spaced apart by at least 4 hr were delivered daily, 5 days a week for six consecutive weeks for a total of 67.5 Gy. Chemotherapy was administered during the same period, which consisted of @entity2903 given at a dose of 75 mg/m(2) for 7 days a week. After a 4-week break, chemotherapy was resumed for up to six cycles of adjuvant @entity2903 treatment, given every 28 days, according to the standard 5-day regimen. Tolerance and @entity137 were the primary endpoints; survival and progression-free survival were the secondary endpoints. In total, 40 @entity1 were enrolled in this study, 29 @entity1 and 11 @entity1 . The median age was 58 years, and the median Karnofsky performance status was 80. The concomitant ultra-fractionated radiotherapy and @entity2903 treatment was well tolerated. Complete responses were seen in four @entity1 , and partial responses were reported in seven @entity1 . The median survival from the initial diagnosis was 16 months. Several long-term survivors were noted. Concurrent ultra-fractionated radiation therapy and @entity2903 treatment are well accepted by the @entity1 . The results showed encouraging survival rates for these unfavorable @entity1 .

A concurrent ultra-fractionated radiation therapy and @entity2903 treatment: A promising therapy for newly diagnosed, inoperable XXXX .

@entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity463 :: ('MESH:D005909', 'Disease') :: ['supratentorial glioblastoma', 'glioblastoma']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
